AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03150758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7Hz + 200 micro-seconds
Description: 7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
Study NCT02696200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Collar
Description: The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
Study NCT06032689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Xtra-fill
Description: the material was placed in bulk.
Study NCT06032689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: x-base
Description: The x-base liner was placed and then veneered with Xtra-fill.
Study NCT06032689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Admira fusion x-tra
Description: bulk placement of the restoration Admira fusion -xtra.
Study NCT06032689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Admira fusion x-base
Description: Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
Study NCT02733484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
Study NCT02733484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patients in this arm will receive placebo intervention
Study NCT02601859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study NCT03676504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR T Cells
Description: Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
Study NCT02708771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids omega-3
Description: 4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
Study NCT03676504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 3 days of fludarabine 30 mg/m\^2/day
Study NCT03676504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 3 days of cyclophosphamide 500 mg/m\^2/day
Study NCT00115895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive iodine
Description: Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
Study NCT00115895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Radioactive iodine
Description: Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
Study NCT05895539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An automated patient-reported outcome data collection and adverse event surveillance tool
Description: Patients received a short prompt to provide information on treatment satisfaction and side effects
Study NCT03190148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OGTT
Description: A standardized 75g oral Glucose tolerance test was accomplished.
Study NCT03190148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IVGTT
Description: For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
Study NCT03190148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
Study NCT03026166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered by intravenous infusion
Study NCT03026166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous infusion
Study NCT03026166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Administered by intravenous infusion
Study NCT01758068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coconut Oil Application
Description: Coconut oil - 4 ml
Study NCT04266821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case.
Study NCT02708771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 daily capsules of similar appearance and flavor without active ingredient
Study NCT01010113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula with prebiotics
Description: From 0-6 months of age. As per standard requirement
Study NCT01010113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with synbiotics
Description: From 0-6 months of age as per standard requirement
Study NCT02198235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02198235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02198235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Study NCT02198235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study NCT05106010 — intervention group
Intervention type: OTHER
Intervention: Balance Flow Yoga
Description: The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
Study NCT02530996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4
Description: BH4 10 mg/kg/day given once to a total of 12 SSc patients
Study NCT02530996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vasculopathy assessment
Description: Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
Study NCT02530996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
Study NCT01742065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auto Plus
Description: Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
Study NCT05620953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: respiratory specimen
Description: nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
Study NCT00042666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY317615
Description: 500 mg, oral, QD, up to six 28 day cycles
Study NCT00805064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone and bevacizumab
Study NCT04608422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
Study NCT04496453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childhood vaccination decision support tool
Description: Participants receive childhood vaccination decision support tool
Study NCT03083223 — intervention group
Intervention type: OTHER
Intervention: position
Description: Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
Study NCT01086852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FACTOR X
Description: Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min.
Study NCT03299283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BioFire test platform
Description: Analysis of analyte stability under various conditions as measured by BioFire test platforms
Study NCT02575703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3023414
Description: LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
Study NCT03006224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Lung Ventilation
Study NCT03000036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
Study NCT03000036 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Achieva, Philips Medical Systems (3T magnet)
Description: Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
Study NCT03000036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gadoterate Meglumine
Description: LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
Study NCT04571996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-104
Description: Capsule
Study NCT04571996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Rapidly dissolving tablet
Study NCT02048371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Study NCT04306835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy for insomnia
Description: a technique for treating insomnia without medications
Study NCT02048371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 days on and 7 days off
Study NCT04698694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)
Description: The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
Study NCT04698694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)
Description: The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
Study NCT00972920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
Study NCT03720496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-TriCAR-T
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
Study NCT00796107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: R1507 was administered at a dose 16 mg/kg every 3 weeks.
Study NCT03375411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent INC1
Description: Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
Study NCT00523250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-102 0.003% Ophthalmic Solution
Study NCT00796107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole was administered orally at a dose 2.5 mg daily.
Study NCT04003792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: intra-arterial oxaliplatin administration
Study NCT04003792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: systemic FOLFIRI chemotherapy
Study NCT04003792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: systemic bevacuzimab therapy
Study NCT03964779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal assay
Description: Measurement of Thyroid stimulating hormone
Study NCT03964779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody assay
Description: antithyroglobulin and antithyroid peroxidase
Study NCT02218554 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRONJ
Description: collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
Study NCT01662401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
Study NCT01662401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
Study NCT03743155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal cells
Description: Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
Study NCT03685812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Autocad software
Description: The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
Study NCT04414618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opaganib
Description: Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
Study NCT04414618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
Study NCT03451357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dependence degree already certificated by Dependence Law.
Description: The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
Study NCT00076349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine and rituximab
Description: Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
Study NCT02108691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycin max(L.) Merr. peel extract
Description: Glycin max(L.) Merr. peel extract (2.5g/day)
Study NCT02108691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2.5g/day)
Study NCT04147546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Additional screening using ultra sensitive RDTs
Description: At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
Study NCT04147546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquin
Description: All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
Study NCT04147546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
Study NCT02858752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 1 : Auditory and Visual Discrimination
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
Study NCT02858752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 2 : Passive and Active Auditory Perception
Description: Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, ...). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.